A comparative study to assess the effect of intense pulsed light therapy with topical 2.5% benzoyl peroxide versus topical 2.5% benzoyl peroxide alone in acne patients

Recruiting

• Conditions: Acne vulgaris,

• Registration Number: CTRI/2022/07/044041
• Lead Sponsor: R Aishwarya Meenaloshini

Brief Summary

To determine and compare the efficacy and safety ofintense-pulsed light therapy with topical benzoyl peroxide 2.5% versus benzoylperoxide 2.5% alone in patients with mild to moderate acne vulgaris

Patientsfulfilling the inclusion criteria will be included in the study after writteninformed consent. Patient’s demographics will be recorded. Detailed history andclinical examination will be done. Duration of the disease, acne grade will berecorded. Total 60 patients will be divided by random sampling into Group A& Group Beach group comprising of 30 patients. 30 patients in Group A will receive 2.5% topical benzoyl peroxide alone dailyat night.30 patients in Group B will receive 2.5% topical benzoyl peroxidedaily at night(except on IPL days) with intense pulse light therapy once in amonth (410nm filter, at 15 J/cm2 40 ms pulse duration in singlepulse mode).

Acne vulgaris is a disease of pilosebaceous unit withmultifactorial pathogenesis. Major factors in acne are hyperactivity of sebaceous glands and involvement ofpropionibacterium acnes bacterium. Acne leaves scar in untreated cases and it can affect an individual’s emotionalwell-being and influence quality of life. Due to multifactorial pathogenesis of acne more desirable results are expectedfrom combination therapies.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-18
• Last Update Posted: 2022-08-16

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• •Patients of both genders above 18 years & below 30 years with acne vulgaris.
• •Not receiving any systemic or topical acne treatment for last 2 weeks.
• •No tendency to develop keloid or hypertrophic scar.
• •Not receiving topical and systemic steroids for last 6 months.
• •Patients willing to give a written informed consent.

Exclusion Criteria

• Before starting the study •Pregnant and lactating women.
• •Women planning for pregnancy •Patients with co-morbidities-DM,SHT,TB,CAD,EPILEPSY,BA,HIV During Study •If patient develops severe side effects during the treatment •If patient wants alternate treatment during the study.
• •If patient wants to discontinue the treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The end point will be the evaluation of clinical response to both the mode of treatment at 16 weeks after treatment initiation. Responses in between the study will be noticed & recorded using Comprehensive Acne Severity Scale(CASS) and patient satisfaction score	16 weeks

Secondary Outcome Measures

Name	Time	Method
To look for reduction of post acne pigmentation following treatment and recurrence	8 weeks

Trial Locations

Locations (1)

Chengalpattu Medical College; 🇮🇳 Kancheepuram, TAMIL NADU, India

Chengalpattu Medical College

🇮🇳Kancheepuram, TAMIL NADU, India

Dr R Aishwarya Meenaloshini

Principal investigator

7598574981

dsraishu@gmail.com